上海海利生物技术股份有限公司 2025 年第二次临时股东会 会议资料 二〇二五年十一月 上海 上海海利生物技术股份有限公司 2025 年第二次临时股东会议程 一、现场会议召开时间 2025 年 11 月 14 日（星期五）13:30 二、网络投票时间 1、互联网投票平台投票时间：2025 年 11 月 14 日的 9:15－15:00 2、交易系统投票平台投票时间：2025 年 11 月 14 日的交易时间段，即 9:15 －9:25，9:30－11:30，13:00－15:00 三、现场会议召开地点 上海市黄浦区淮海中路 138 号 805 室 （三）推举两名监票人、一名计票人，并宣读议案审议和表决办法 （四）宣读和审议会议议案 1、关于聘任公司 2025 年度会计师事务所的议案 上述议案采用非累积投票方式表决。 四、会议主持 董事长张海明先生 五、会议议程 （一）主持人宣布 2025 年第二次临时股东会开始，报告出席会议的股东人 数及代表股份总数 （二）介绍出席会议的董事、高级管理人员、见证律师等人员情况 （五）股东发言、提问及公司回答 （六）现场会议投票表决 1、股东填写表决票 2、计票人、监票人计票 ...

Group 1 - The agricultural, animal husbandry, and fishery sector showed strong performance, with the only agricultural ETF (159275) rising by 1.21% at the close [1][2] - Key stocks in the sector included edible fungi, pig farming, and seeds, with notable gains from companies like Zhongxing Junye and Luoniushan, both hitting the daily limit [1][3] - The recent rebound in pig prices, with an increase of 6.1% from the previous week, has positively impacted the sector [2][3] Group 2 - Short-term pressure on pig sales has eased, with a decrease in the overall output from large enterprises and an increase in secondary fattening [3][4] - The industry is expected to focus on quality improvement and efficiency, with a gradual elimination of outdated production capacity [4][5] - The agricultural ETF (159275) is currently at a relatively low price-to-book ratio of 2.56, indicating a good long-term investment opportunity [3][5] Group 3 - The agricultural ETF tracks the CSI Agricultural, Animal Husbandry, and Fishery Index, with a significant concentration in leading companies in the sector, including Muyuan Foods and Wens Foodstuffs [5][6] - Investors can also access the agricultural ETF through linked funds for broader exposure to the sector [5]

Core Insights - The animal health sector experienced a decline of 0.35% on November 3, with Reap Bio leading the losses [1] - The Shanghai Composite Index closed at 3976.52, up 0.55%, while the Shenzhen Component Index closed at 13404.06, up 0.19% [1] Stock Performance Summary - Hai Li Biological (603718) closed at 7.02, up 2.03% with a trading volume of 101,600 shares and a turnover of 70.93 million yuan [1] - Shen Lian Biological (688098) closed at 11.36, up 1.43% with a trading volume of 133,100 shares and a turnover of 150 million yuan [1] - Yong Shun Biological (920729) closed at 10.09, up 1.00% with a trading volume of 23,800 shares and a turnover of 24.09 million yuan [1] - The worst performer was Reap Bio (300119), which closed at 21.01, down 2.51% with a trading volume of 103,300 shares and a turnover of 219 million yuan [2] Capital Flow Analysis - The animal health sector saw a net outflow of 35.26 million yuan from institutional investors, while retail investors had a net inflow of 26.79 million yuan [2] - The main capital inflow was observed in Shen Lian Biological, with a net inflow of 4.03 million yuan from institutional investors [3] - Conversely, Reap Bio experienced a net outflow of 1.29 million yuan from institutional investors [3]

Market Overview - The animal health sector experienced a decline of 2.79% on October 30, with Jinhe Biology leading the drop [1] - The Shanghai Composite Index closed at 3986.9, down 0.73%, while the Shenzhen Component Index closed at 13532.13, down 1.16% [1] Individual Stock Performance - Jinhe Biology (002688) closed at 6.25, down 7.13% with a trading volume of 578,000 shares and a transaction value of 367 million yuan [1] - Keqian Biology (688526) closed at 16.15, down 6.76% with a trading volume of 139,800 shares and a transaction value of 228 million yuan [1] - Maofeng Holdings (002141) closed at 3.92, down 5.08% with a trading volume of 461,300 shares and a transaction value of 18.3 million yuan [1] - Other notable declines include Dayu Biology (920970) down 2.69%, and Pulaike (603566) down 2.68% [1] Capital Flow Analysis - The animal health sector saw a net outflow of 84.7 million yuan from institutional investors, while retail investors experienced a net outflow of 16.5 million yuan [1] - Speculative funds recorded a net inflow of 101 million yuan [1] Detailed Capital Flow for Selected Stocks - Keqian Biology (688526) had a net inflow of 39.6 million yuan from institutional investors, while retail investors saw a net outflow of 60.9 million yuan [2] - Huisheng Biology (300871) experienced a net inflow of 18.3 million yuan from institutional investors, with a net outflow of 21.2 million yuan from retail investors [2] - Other stocks like Pulaike (603566) and Maofeng Holdings (002141) also reported significant net outflows from institutional investors [2]

Core Viewpoint - The company has announced significant changes regarding its stock incentive plan, including the repurchase and cancellation of certain restricted stocks and stock options due to unmet performance conditions and employee departures [52][64][66]. Financial Data - The company reported a cash dividend of 0.0784 yuan per share, totaling approximately 51.4 million yuan distributed to shareholders [5]. - The total number of shares will decrease from 655,662,200 to 651,904,700 after the repurchase of 3,757,500 restricted stocks [50][66]. Board Meeting and Resolutions - The fifth board meeting was held on October 28, 2025, where several key resolutions were passed, including the approval of the third-quarter report and the adjustment of the stock incentive plan [10][12][58]. - The board approved the appointment of Sigma Accounting Firm for the 2025 financial audit [12]. Stock Incentive Plan Adjustments - The company will repurchase 243,750 restricted stocks due to unmet conditions for the second release period of the stock incentive plan [64][66]. - The repurchase price for restricted stocks has been adjusted to 4.6729 yuan per share, and the exercise price for stock options has been adjusted to 9.4429 yuan per option [61][63]. Upcoming Events - The company will hold a second extraordinary general meeting on November 14, 2025, to discuss the resolutions passed by the board [20][32]. - An investor performance briefing is scheduled for November 21, 2025, to discuss the third-quarter results and address investor inquiries [24][25].

Core Insights - The company reported a revenue of 149,742,032.70 yuan for the first three quarters of 2025, representing a year-on-year decline of 14.15% [2] - The net profit attributable to shareholders of the listed company was 20,329,681.80 yuan, showing a slight year-on-year increase of 0.77% [2] Financial Performance - Revenue for the first three quarters of 2025: 149.74 million yuan, down 14.15% year-on-year [2] - Net profit for the same period: 20.33 million yuan, up 0.77% year-on-year [2]

Group 1 - The core viewpoint of the article is that Haili Biological (603718.SH) reported a decline in total operating revenue for the first three quarters of 2025, while net profit attributable to shareholders showed a slight increase [1] Group 2 - For the first three quarters of 2025, the company achieved total operating revenue of 150 million yuan, representing a year-on-year decrease of 14.15% [1] - The net profit attributable to shareholders was 20.33 million yuan, which is a year-on-year increase of 0.77% [1] - The basic earnings per share were reported at 0.031 yuan [1]

证券代码：603718 证券简称：海利生物 公告编号：2025－048 上海海利生物技术股份有限公司 关于公司 2023 年限制性股票与股票期权激励计划限制性股 票第二个解除限售期解除限售条件未成就暨调整回购价格及 行权价格并回购注销部分限制性股票与部分股票期权注销的 公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 上海海利生物技术股份有限公司（以下简称"公司"）于2025年10月28日召 开第五届董事会第十六次会议，审议通过了《关于公司2023年限制性股票与股票 期权激励计划限制性股票第二个解除限售期解除限售条件未成就暨调整回购价格 及行权价格并回购注销部分限制性股票与部分股票期权注销的议案》。具体情况 如下： 一、股权激励计划批准及实施情况 1、2023年8月18日，公司召开第四届董事会第十五次会议，审议通过了《关 于<上海海利生物技术股份有限公司2023年限制性股票与股票期权激励计划（草 案）>及其摘要的议案》《关于公司<2023年限制性股票与股票期权激励计划实施 考核管理办法>的议案》《关于提请股 ...

上海市通力律师事务所 关于上海海利生物技术股份有限公司 2023 年限制性股票与股票期权激励计划限制性股票第二个 解除限售期解除限售条件未成就暨调整回购价格、行权价格 及回购注销、注销事项的法律意见书 致: 上海海利生物技术股份有限公司 敬启者: 上海市通力律师事务所(以下简称"本所")受上海海利生物技术股份有限公司(以下简称 "海利生物"或"公司")委托, 指派张征轶律师、蔡丛丛律师(以下简称"本所律师")作为 公司特聘专项法律顾问, 根据《中华人民共和国公司法》(以下简称"《公司法》")、《中华人 民共和国证券法》(以下简称"《证券法》")、《上市公司股权激励管理办法》(以下简称"《管 理办法》")、《上海证券交易所股票上市规则(2025 年 4 月修订)》等法律、行政法规和其他 规范性文件(以下简称"法律、法规和规范性文件")的有关规定以及公司为 2023 年限制性 股票与股票期权激励计划(以下简称"本次激励计划")制订的《上海海利生物技术股份有限 公司 2023 年限制性股票与股票期权激励计划》(以下简称"《激励计划》"), 就海利生物本 次激励计划限制性股票第二个解除限售期解除限售条件未成就暨调整回 ...

证券代码：603718 证券简称：海利生物 公告编号：2025－050 上海海利生物技术股份有限公司 关于变更注册资本并修订《公司章程》的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 上海海利生物技术股份有限公司（以下简称"公司"）于 2025 年 10 月 28 日 召开第五届董事会第十六次会议，审议通过了《关于变更公司注册资本并修订< 公司章程>的议案》。现将有关情况公告如下： 2025 年 10 月 28 日，公司召开第五届董事会第十六次会议，审议通过了《关 于公司 2023 年限制性股票与股票期权激励计划限制性股票第二个解除限售期解 除限售条件未成就暨调整回购价格及行权价格并回购注销部分限制性股票与部分 股票期权注销的议案》。公司拟回购注销因激励对象离职、考核未达标等原因涉及 已获授但尚未解除限售的共计 375.75 万股限制性股票。回购注销完成后，公司股 份总数将由 655,662,200 股变更为 651,904,700 股，注册资本将由 655,662,200 元 变更为 651,904,700 元 ...